Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR-PET/MR in Newly Diagnosed Prostate Cancer
NCT03307460Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NOTA-AE105 in prostate cancer (PCa), sponsored by Rigshospitalet. Primary endpoint: Correlation with Gleason Score at 3 months. Status: unknown.
02
Drugs
68Ga-NOTA-AE105
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03307460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307460.